OBJECTIVES: Measuring the cost-effectiveness of interventions for adult growth hormone deficiency (AGHD) requires estimates of the benefits. For the purposes of cost-utility analysis those benefits should be expressed as QALYs. Where primary outcomes data are collected using condition-sensitive measures of health-related quality of life (HrQoL) then recalibration is necessary. This paper reports the use of EQ-5D as a mechanism for converting such data into a useable QALY metric. METHODS: QoL-AGHDA is a 25-item questionnaire designed for use in AGHD. Yes/no responses are used to compute a summary index with a high score denoting poor HrQoL. A total of 1000 individuals randomly selected from the UK Population Preference Panel were sent a copy of QoL-AGHDA together with EQ-5D, a widely used generic measure of HrQoL calibrated in terms of TTO preference weights. Corresponding QoL-AGHDA data on patients (n=836) was made available from UK KIMS (Pfizer International Metabolic Database). RESULTS: Completed survey forms were received from 882 individuals (57% female, median age 55). There was a high degree of correlation between EQ-5D and QOL-AGHDA summary score (r=-0.529, p<0.001). Age/gender standardised mean EQ-5D index scores were computed for different categories of QoL-AGHDA score in the general population survey. These were used as a lookup table to provide estimates of EQ-5D for each patient in the KIMS dataset according to their age/gender and QoL-AGHDA score. Within-year QALY losses between the EQ-5D index for KIMS patients and corresponding EQ-5D for the general population. Using age-specific prevalence data together with the relevant population life expectancy tables, it was also possible to estimate potential lifetime QALY losses for GHD. CONCLUSIONS: AGHD patients record lower levels of HrQoL than the general population. This difference equates to a 0.15 QALY “loss” per annum and a lifetime loss across all GHD patients of some 40,000 QALYs.